Greece to reduce prices, halt reimbursement on some drugs

The price of certain drugs in Greece will be reduced 10.41 percent, Pharma Times is reporting. The drugs involved have not been identified, but analysts at IHS Global Insight suggest that they will include biotechnology drugs used in the treatment of cancer, and possibly some orphan products. Regulators are also creating a second list of medicines which will no longer be eligible for reimbursement. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.